
NextCure Inc NXTC.OQ NXTC.O is expected to show no change in quarterly revenue when it reports results on April 30 (estimated) for the period ending March 31 2025
LSEG's mean analyst estimate for NextCure Inc is for a loss of 40 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for NextCure Inc is $3.00, above its last closing price of $0.46.
This summary was machine generated April 28 at 11:34 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)